Rapid Micro Biosystems Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Rapid Micro Biosystems Inc 's ROA in the second quarter of 2026?
Rapid Micro Biosystems Inc recorded a cumulative net loss of $0 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -0.1%.

However, within the Healthcare sector 214 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 2555, from total ROA ranking in the first quarter of 2026 at 2935.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	1.37 %	-27 %	-23.75 %	-20.25 %	-35.64 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	0	0	0	0	0
Return On Assets (TTM)	-0.1 %	-0.06 %	-0.05 %	-0.02 %	-0.02 %
RPID's Total Ranking	# 2555	# 2935	# 2562	# 2556	# 2577
Total Assets (TTM) in million	76	62	75	84	75
Seq. Total Assets Change	22.48 %	-16.68 %	-11.32 %	12.02 %	-11.8 %
Seq. Net Income Change	-	-	-	-	-

RPID's 5 Years Annual ROA >> Back to RPID Management Effectiveness >> Compare RPID ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 9
Sector	# 215
Overall	# 2546

Return On Assets Statistics
High	Average	Low
-0.02 %	-11 %	-42.33 %
		(Dec 31 2021)

Financial Statements
Rapid Micro Biosystems Inc 's Assets	$ 76 million	RPID's Balance sheet
Rapid Micro Biosystems Inc 's Income	$ 0 million	Quarterly RPID's Income Statement
RPID's Income by Division		See RPID's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-23.75 %	-35.65 %	-20.62 %	-20.31 %	-
Total Assets in million	75	98	153	192	241
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	0	0	-52	1	-74
Annual Return On Assets	-0.05 %	-0.02 %	-34.39 %	0.3 %	-30.49 %

RPID's 5 Years Annual ROA >> Back to RPID Management Effectiveness >> Compare RPID ROA to its Competitors

More Return On Assets Ratios
RPID's' Return on Assets at Yahoo Finance
Laboratory Analytical Instruments Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RPID's Roa Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RPID's Competitors
Subscribers only: Roa for Rapid Micro Biosystems Inc 's Suppliers
Subscribers only: Return On Assets for RPID's Customers

You may also want to know
RPID's Roi	RPID's Inventory Turnover Ratio	RPID's Growth Rates	RPID's Dividend Comparisons
	RPID's Profitability Ratios	RPID's Asset Turnover Ratio	RPID's Dividend Growth
RPID's Roe	RPID's Valuation Ratios	RPID's Financial Strength Ratios	RPID's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:40:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.